Phase III METIS: Tumor treating fields following radiosurgery for brain mets

Minesh P. Mehta, MD, FASTRO, Miami Cancer Institute, Miami, FL, shares details of the ongoing Phase III METIS study (NCT02831959), evaluating the use of tumor treating fields (TTFields) in patients with non-small cell lung cancer (NSCLC) with brain metastases. TTFields are a non-invasive loco-regional treatment modality that uses alternating electric fields to cause DNA damage. The trial randomized patients to receive stereotactic radio surgery, followed either by continuous TTFields -delivered through an experimental portable device- or supportive care. First intercranial progression was set as the primary trial endpoint. An early data review identified no unexpected safety issues and trial accrual is ongoing. This interview took place during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021.